RARX Ra Pharmaceuticals Inc.

16.29
-0.19  -1%
Previous Close 16.48
Open 16.55
Price To Book 6.57
Market Cap 527763844
Shares 32,398,026
Volume 626,711
Short Ratio
Av. Daily Volume 430,171

SEC filingsSee all SEC filings

  1. 8-K - Current report 181234481
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181231636
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181229705
  4. 8-K - Current report 181229541
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181227577

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met endpoints - December 10, 2018. Phase 3 planned.
RA101495 zilucoplan
Myasthenia Gravis (MG)
Phase 3 trial to be initiated 1H 2019.
RA101495
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1b PK data released September 26, 2018.
RA101495 SC
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  2. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  3. Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today
  4. Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
  5. Here's Why Ra Pharmaceuticals Inc. Is Soaring Today
  6. Ra Pharma Shares Rally: What You Need To Know
  7. Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
  8. Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
  9. Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
  10. ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  11. Ra Pharmaceuticals to Present at Upcoming Investor Conferences
  12. Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?
  13. Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
  14. Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
  15. Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
  16. Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
  17. Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
  18. Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
  19. Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology

SEC Filings

  1. 8-K - Current report 181234481
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181231636
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181229705
  4. 8-K - Current report 181229541
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181227577
  6. 8-K - Current report 181226314
  7. 8-K - Current report 181187571
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166477
  9. 8-K - Current report 181084830
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999737